-transparent.png){kind=logo}
21 schizophrenic patients were treated in a single blind study with para-chlorphenyl-GABA (baclofen) for 20 days after a placebo period of at least 1 week. Global clinical impression identified five patients as behaviorally unchanged, seven as improved and nine as worsened during the active drug administration. Four patients had to be withdrawn from the trial because of serious and unmanageable psychotic exacerbations. Overall incidence of psychotic symptoms in the group of the schizophrenic patients did not change substantially neither did the remission coefficient as calculated from the AMP documentation system. No differential effect was detected either on selected Schneiderian first rank symptoms or on symptoms more characteristic for chronic defectuous schizophrenia. It is concluded that baclofen is not a useful drug in the therapy of schizophrenia.
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
January 1977,
Psychopharmacology bulletin,
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
May 1976,
Lancet (London, England),
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
October 1988,
Psychiatry research,
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
February 1975,
Lakartidningen,
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
April 1997,
Chest,
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
January 1977,
Advances in biochemical psychopharmacology,
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
August 2013,
Molecules (Basel, Switzerland),
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
March 1975,
Lancet (London, England),
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
June 1994,
The Journal of experimental biology,
H Beckmann, and
M Frische, and
E Rüther, and
R Zimmer
March 1981,
Nature,
